Patrick Y Wen
Neurology — Dana-Farber Cancer Institute, United States
Patrick Y Wen
LeadR Profile
Neurology
Subspecialties: Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1991 - 2026
Number : 1184
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Prognostic Significance of Contrast Enhancement in Newly Diagnosed Grade 2 IDH-mutant Glioma. brain neoplasms, glioma | Neuro Oncol | 2026 | 0 |
| Clinical trial designs in the era of biomarker-guided therapies. brain neoplasms, biomarkers, therapeutics | Neuro Oncol | 2026 | 0 |
| Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial. neoplasms, glioblastoma, nivolumab | Nat Commun | 2026 | 0 |
| Timing and prognosis of brain metastasis development in breast cancer by subtype. breast neoplasms, brain, neoplasms, neoplasm metastasis, breast, diagnosis, prognosis | JNCI Cancer Spectr | 2026 | 0 |
| Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY). astrocytoma, neoplasms, glioblastoma | Eur J Cancer | 2026 | 0 |
Clinical Studies 54
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 5
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence NCT06336291 — lomustine, glioblastoma | Phase 2 | Active not recruiting | 2024 |
| Surgical Nivolumab And Ipilimumab For Recurrent GBM NCT04606316 — research design, pharmaceutical preparations, astrocytoma, surgical procedures, operative, drugs, investigational, solutions, glioblastoma, nivolumab, therapeutics, ipilimumab, tissues, veins | Phase 1 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map